Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)

Last updated: October 15, 2024
Sponsor: Cedars-Sinai Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Adenocarcinoma

Treatment

6D-MRI

Clinical Study ID

NCT04700488
STUDY00000573
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Pancreatic cancer patients (with resectable or borderline resectable or locallyadvanced tumors) who will undergo neoadjuvant chemotherapy

  • Patients able to undergo at least two sets of MRI sessions

  • Access to a device that has the capability to sync to the Fitbit (or access to afamily member's, caregiver's, or friend's device)

Exclusion

Exclusion Criteria:

  • Patients who have previously been treated for PDAC

  • Patients unable to undergo MRI exam w/contrast

  • Patients with metastatic pancreatic cancer visualized on index diagnostic imaging

  • Patients with certain metallic implants

  • Patients experiencing claustrophobia

Study Design

Total Participants: 36
Treatment Group(s): 1
Primary Treatment: 6D-MRI
Phase:
Study Start date:
May 19, 2022
Estimated Completion Date:
January 31, 2026

Study Description

The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e. vascularity, fibrosis), to predict PDAC response to neoadjuvant therapy (NAT).

Connect with a study center

  • Cedars-Sinai Medical Center

    Los Angeles, California 90048
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.